Other Species / Isoforms
  FBXO31 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
R14-m1
LCGVGPSrGCRRRQQ
0 1
FBXO31 (human) LCGVGPSrGCRRRQQ R14-m1
FBXO31 (mouse) LCGVGPARGCRRRQQ R14
FBXO31 (rat) LCGVGPARGCRRRQQ R14
R14-m2
LCGVGPSrGCRRRQQ
0 1
FBXO31 (human) LCGVGPSrGCRRRQQ R14-m2
FBXO31 (mouse) LCGVGPARGCRRRQQ R14
FBXO31 (rat) LCGVGPARGCRRRQQ R14
S33-p
AETAAADsEPDtDPE
Upstream
Downstream
1 15
Effects on Modified Protein
  • protein degradation
  • ubiquitination
Kinase, in vitro:
  • Akt1 (human)
Treatment
  • ionizing_radiation
FBXO31 (human) AETAAADsEPDtDPE S33-p
FBXO31 (mouse) AETAAADsEADtDPE S33-p
FBXO31 (rat) AETAAADsEADtDPE S33-p
T37-p
AADsEPDtDPEEERI
0 15
FBXO31 (human) AADsEPDtDPEEERI T37-p
FBXO31 (mouse) AADsEADtDPEEERI T37-p
FBXO31 (rat) AADsEADtDPEEERI T37-p
T127-p
NLRKLEItGVSCRDV
0 1
FBXO31 (human) NLRKLEItGVSCRDV T127-p
FBXO31 (mouse) NLRKLEITGVSCRDV T113
FBXO31 (rat) NLRKLEITGVSCRDV T113
Y135-p
GVSCRDVyAKLLHRY
0 1
FBXO31 (human) GVSCRDVyAKLLHRY Y135-p
FBXO31 (mouse) GVSCRDVYAKLLHRY Y121
FBXO31 (rat) GVSCRDVYAKLLHRY Y121
K189
VDDPMRFKPLFRIHL
0 1
FBXO31 (human) VDDPMRFKPLFRIHL K189
FBXO31 (mouse) VGDPMRFKPLFRIHL K175
FBXO31 (rat) VGDPMRFkPLFRIHL K175-ac
K229-ub
KKDEFSTkCNQTDHH
0 2
FBXO31 (human) KKDEFSTkCNQTDHH K229-ub
FBXO31 (mouse) KRDEFSTkCNQTDHH K215-ub
FBXO31 (rat) KRDEFSTKCNQTDHH K215
Y276-p
LILMKFIytsQYDNC
0 1
FBXO31 (human) LILMKFIytsQYDNC Y276-p
FBXO31 (mouse) LILMKFIYTSQYDNC Y262
FBXO31 (rat) LILMKFIYTSQYDNC Y262
T277-p
ILMKFIytsQYDNCL
0 1
FBXO31 (human) ILMKFIytsQYDNCL T277-p
FBXO31 (mouse) ILMKFIYTSQYDNCL T263
FBXO31 (rat) ILMKFIYTSQYDNCL T263
S278-p
LMKFIytsQYDNCLt
Upstream
Downstream
2 0
Effects on Modified Protein
  • molecular association, regulation
  • protein stabilization
Kinase, in vitro:
  • ATM (human)
Putative in vivo kinases:
  • ATM (human)
FBXO31 (human) LMKFIytsQYDNCLt S278-p
FBXO31 (mouse) LMKFIYTSQYDNCLT S264
FBXO31 (rat) LMKFIYTSQYDNCLT S264
T285-p
sQYDNCLtyRRIYLP
0 1
FBXO31 (human) sQYDNCLtyRRIYLP T285-p
FBXO31 (mouse) SQYDNCLTYRRIYLP T271
FBXO31 (rat) SQYDNCLTYRRIYLP T271
Y286-p
QYDNCLtyRRIYLPP
0 1
FBXO31 (human) QYDNCLtyRRIYLPP Y286-p
FBXO31 (mouse) QYDNCLTYRRIYLPP Y272
FBXO31 (rat) QYDNCLTYRRIYLPP Y272
T308-p
KPGLFKGtyGsHGLE
0 1
FBXO31 (human) KPGLFKGtyGsHGLE T308-p
FBXO31 (mouse) KPGLFKGTYGSHGLE T294
FBXO31 (rat) KPGLFKGTYGSHGLE T294
Y309-p
PGLFKGtyGsHGLEI
0 1
FBXO31 (human) PGLFKGtyGsHGLEI Y309-p
FBXO31 (mouse) PGLFKGTYGSHGLEI Y295
FBXO31 (rat) PGLFKGTYGSHGLEI Y295
S311-p
LFKGtyGsHGLEIVM
0 1
FBXO31 (human) LFKGtyGsHGLEIVM S311-p
FBXO31 (mouse) LFKGTYGSHGLEIVM S297
FBXO31 (rat) LFKGTYGSHGLEIVM S297
K330-ub
GRRARGTkITGDPNI
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
  • protein degradation
  • ubiquitination
FBXO31 (human) GRRARGTkITGDPNI K330-ub
FBXO31 (mouse) GSRARGTKITGDPNI K316
FBXO31 (rat) GSRARGTKITGDPNI K316